Evidence map›Paper›PMID 25638582›Full record

ArticleClinical autonomic research : official journal of the Clinical Autonomic Research Society2015

Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.

David S Goldstein, Irwin J Kopin, Yehonatan Sharabi, Courtney Holmes

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. 3,4-Dihydroxyphenylglycol levels separate multiple system atrophy from Parkinson disease with orthostatic hypotension.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Observational
  3. Diagnosing multiple system atrophy at the prodromal stage.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020
    Review
  4. Review
  5. Observational
  6. Review
  7. Diagnosis of multiple system atrophy.Autonomic neuroscience : basic & clinical · 2018
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

David S GoldsteinClinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH), 10 Center Drive MSC-1620, Building 10 Room 5N220, Bethesda, MD, 20892-1620, USA, goldsteind@ninds.nih.gov.
Irwin J Kopin
Yehonatan Sharabi
Courtney Holmes
National Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USSheba Medical Center · IL

Funding

Biomarkers of Parkinson Disease and Related DisordersZIANS003034 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2009 to 2025
$22.8M
Biomarkers of Parkinson Disease and Related DisordersZ01NS003034 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2007 to 2008
$3.9M
Intramural NIH HHS Z01 NS003034Intramural NIH HHS Z99 NS999999
6 · The paper itself

Abstract

backgroundParkinson disease with orthostatic hypotension (PD + OH) and the parkinsonian form of multiple system atrophy (MSA-P) can be difficult to distinguish clinically. Recent studies indicate that PD entails a vesicular storage defect in catecholaminergic neurons. Although cardiac sympathetic neuroimaging by (18)F-dopamine positron emission tomography can identify decreased vesicular storage, this testing is not generally available. We assessed whether plasma biomarkers of a vesicular storage defect can separate PD + OH from MSA-P.

methodsWe conceptualized that after F-dopamine injection, augmented production of F-dihydroxyphenylacetic acid (F-DOPAC) indicates decreased vesicular storage, and we therefore predicted that arterial plasma F-DOPAC would be elevated in PD + OH but not in MSA-P. We measured arterial plasma F-DOPAC after (18)F-dopamine administration (infused i.v. over 3 min) in patients with PD + OH (N = 12) or MSA-P (N = 21) and in healthy control subjects (N = 26). Peak F-DOPAC:dihydroxyphenylglycol (DHPG) was also calculated to adjust for effects of denervation on F-DOPAC production.

resultsPlasma F-DOPAC accumulated rapidly after initiation of (18)F-dopamine infusion. Peak F-DOPAC (5-10 min) in PD + OH averaged three times that in MSA-P (P < 0.0001). Among MSA-P patients, none had peak F-DOPAC > 300 nCi-kg/cc-mCi, in contrast with 7 of 12 PD + OH patients (χ(2) = 16.6, P < 0.0001). DHPG was lower in PD + OH (3.83 ± 0.36 nmol/L) than in MSA-P (5.20 ± 0.29 nmol/L, P = 0.007). All MSA-P patients had peak F-DOPAC:DHPG < 60, in contrast with 9 of 12 PD + OH patients (χ(2) = 17.5, P < 0.0001). Adjustment of peak F-DOPAC for DHPG increased test sensitivity from 58 to 81% at similar high specificity.

interpretationAfter F-dopamine injection, plasma F-DOPAC and F-DOPAC:DHPG distinguish PD + OH from MSA-P.

Indexed as

3,4-Dihydroxyphenylacetic AcidAgedBiomarkersCase-Control StudiesComorbidityCross-Sectional StudiesDiagnosis, DifferentialDopamineFemaleFluorine RadioisotopesHumansHypotension, OrthostaticMaleMethoxyhydroxyphenylglycolMiddle AgedMultiple System Atrophy3,4-Dihydroxyphenylacetic Acid3,4-dihydroxyphenylglycolBiomarkersDopamineFluorine RadioisotopesMethoxyhydroxyphenylglycol

Identifiers

PMID25638582
PMCPMC5248558
OpenAlexW1991794216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.